問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Endocrinology

Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

更新時間：2023-09-19

吳順生
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳順生

CHANGHUA CHRISTIAN HOSPITAL

未分科

List

3Cases

2020-11-06 - 2023-12-26

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2020-12-02 - 2022-07-26

Phase II

Phase llb Multi=Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy a and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis Z Virus(B-Clear)nd Safety

  • Condition/Disease

    Patients with chronic hepatitis B virus

  • Test Drug

    GSK3228836

Participate Sites
4Sites

Recruiting4Sites

2019-10-01 - 2023-07-17

Phase III

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

  • Condition/Disease

    D-LIVR

  • Test Drug

    Lonafarnib

Participate Sites
6Sites

Recruiting6Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB